TREATMENT OF UPPER AND LOWER RESPIRATORY-TRACT INFECTIONS - CLINICAL-TRIALS WITH CEFPROZIL

The oral second generation cephalosporin cefprozil has a broad spectru m microbiologic profile, with good in vitro activity against respirato ry pathogens; 90% or more of Streptococcus pneumoniae, Haemophilus inf luenzae and Moraxella catarrhalis isolates are susceptible to cefprozi l, Clinical trials of cefprozil have consistently demonstrated good cl inical success rates in upper and lower respiratory tract infections, including otitis media, sinusitis, pharyngitis/tonsillitis and acute b acterial exacerbations of chronic bronchitis. Most recently cefprozil has demonstrated success in children with recurrent and persistent acu te otitis media. Data from clinical trials including more than 4000 ch ildren and adults have shown that cefprozil is well-tolerated. The mos t common adverse events associated with cefprozil are gastrointestinal disturbances (i.e. diarrhea and nausea), In two patient satisfaction surveys (pediatric and adult), cefprozil was cited for having a low in cidence of side effects and was rated by children as having a pleasing taste, These data indicate that cefprozil is a practical therapeutic choice for the treatment of upper and lower respiratory tract infectio ns.